| Revenue growth | 13% YoY growth in Q1FY27. |
|---|---|
| Margins | Margins under pressure across major segments due to cost escalation. |
| Order book | Strong order bookings driven by data centers. |
| Demand visibility | Strong momentum in industrial, retail, health care, and data centers. |
Growth
Revenue up 13% to ₹3378 cr; EBITDA down 13% to ₹175 cr; PBT (bei) down 24% to ₹126 cr.
Outlook
Expanding presence in US and Europe; focus on data centers and industrial segments for growth.
Risks
Rising input costs, INR depreciation, muted deep freezer demand, and regulatory uncertainty in Med-Tech business.
Last quarter's promises, checked
Delivered
- Guided 15% real volume growth + 10% price hikes → delivered 13% Q1 revenue (= PARTIAL)
- Guided Segment 1 margin 7%-7.5% → delivered 6.5% (= MISS)
- Guided Segment 2 margin 8%-8.5% → delivered 10.4% (= BEAT)
Partly delivered
- Guided Sri City 100% capacity utilization → delivered growth but margins hit (= PARTIAL)
Missed
- Guided 13% price hike to cover costs → delivered margin decline (= MISS)
- Guided PBT growth → delivered PBT (bei) down 24% (= MISS)
Investor Presentation filed with BSE, NSE: BLUESTARCO. Summary written with AI assistance from the document.
Blue Star Ltd: key numbers
- Share price
- ₹1,565.00
- Market cap
- ₹32,179 Cr
- Revenue (annual)
- ₹12,402 Cr
- Net profit (annual)
- ₹527.7 Cr
- P/E (TTM)
- 63.2×Sector 45.9×
- Promoter holding
- 36.50%+0.01% QoQ
- FII holding
- 12.75%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Blue Star Ltd
All →Blue Star Annual General Meeting
Blue Star Limited has issued a Postal Ballot notice seeking shareholder approval for the appointment of Mr. Nikhilesh Panchal as an Independent Director.
Blue Star Legal & Regulatory
Blue Star Limited informed that W.J. Towell & Co LLC has filed an annulment petition in the Dubai Court of Appeal challenging a prior favourable arbitration award.
Blue Star Debt & Borrowing: ₹100 Cr
Blue Star Limited has fixed September 18, 2026, as the record date for its listed Commercial Paper. The maturity amount for this security is Rs. 100 Crores.
- Value
- ₹100.0 Cr
Blue Star Merger & Restructuring Worth ₹40 Cr
Blue Star Limited completed the slump sale of its MedTech division, housed under subsidiary Blue Star E&E, to Cyrix Healthcare for Rs 40 Crore.
- Value
- ₹40.00 Cr
Blue Star Earnings Call Transcript: Key Takeaways
Blue Star missed margin expectations significantly due to inability to pass on commodity costs and a delayed summer. While revenue grew 13%, operational performance was hit by high-cost inventory and aggressive discounting to maintain market share.
- Call
- Guides 18% growth
Blue Star Q1 FY27 Results: Net Profit ₹102.5 Cr, Down 15.1% YoY
Blue Star Ltd reported revenue from operations of ₹3,378 Cr (+13.3% YoY) and net profit of ₹102.5 Cr (-15.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹102.5 Cr · -15.1% YoY